Skip to main content
SpringerLink
Log in

Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies

  • Chapter
  • First Online:
Vitiligo

  • 976 Accesses

Abstract

The development of immunotherapies has remarkably improved the efficacy of treatment of patients with metastatic melanoma, as observed for example with immune checkpoint therapies targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) or programmed cell death-1 (PD-1). Nonetheless, reinstatement of an effective antitumor immune response also contributes to the development of immune-related adverse events, including vitiligo-like depigmentation. This review aims to discuss special considerations in vitiligo-like lesions occurring in patients receiving anti-PD-1 therapies from a clinical and physiopathological perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773–81.

    Article  CAS  Google Scholar 

  2. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51.

    Article  Google Scholar 

  3. Larsabal M, Marti A, Jacquemin C, Rambert J, Thiolat D, Dousset L, et al. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol. 2017;76(5):863–70.

    Article  Google Scholar 

  4. Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. J Hematol Oncol. 2017;10(1):88.

    Article  Google Scholar 

  5. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014;15(7):e257–67.

    Article  CAS  Google Scholar 

  6. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.

    Article  CAS  Google Scholar 

  7. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

    Article  CAS  Google Scholar 

  8. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10(8):1338–43.

    Article  CAS  Google Scholar 

  9. Boasberg PD, Hoon DS, Piro LD, Martin MA, Fujimoto A, Kristedja TS, et al. Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol. 2006;126(12):2658–63.

    Article  CAS  Google Scholar 

  10. Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med. 2015;13:211.

    Article  Google Scholar 

  11. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19(1):81–4.

    Article  CAS  Google Scholar 

  12. Sibaud V, David I, Lamant L, Resseguier S, Radut R, Attal J, et al. Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Res. 2015;25(6):555–8.

    Article  CAS  Google Scholar 

  13. Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016;60:12–25.

    Article  CAS  Google Scholar 

  14. Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016;28(4):254–63.

    Article  CAS  Google Scholar 

  15. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–94.

    Article  CAS  Google Scholar 

  16. Goldinger SM, Stieger P, Meier B, Micaletto S, Contassot E, French LE, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res. 2016;22(16):4023–9.

    Article  CAS  Google Scholar 

  17. Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S, et al. Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol. 2016;74(3):455–61.e1.

    Article  Google Scholar 

  18. Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151(11):1206–12.

    Article  Google Scholar 

  19. Nakamura Y, Tanaka R, Asami Y, Teramoto Y, Imamura T, Sato S, et al. Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J Dermatol. 2017;44(2):117–22.

    Article  CAS  Google Scholar 

  20. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012;72(20):5209–18.

    Article  CAS  Google Scholar 

  21. Byrne KT, Cote AL, Zhang P, Steinberg SM, Guo Y, Allie R, et al. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest. 2011;121(5):1797–809.

    Article  CAS  Google Scholar 

  22. Hsiao JJ, Fisher DE. The roles of microphthalmia-associated transcription factor and pigmentation in melanoma. Arch Biochem Biophys. 2014;563:28–34.

    Article  CAS  Google Scholar 

  23. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med. 2006;12(9):406–14.

    Article  CAS  Google Scholar 

  24. Kawakami Y, Suzuki Y, Shofuda T, Kiniwa Y, Inozume T, Dan K, et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res. 2000;13(Suppl 8):163–9.

    Article  Google Scholar 

  25. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996;184(6):2207–16.

    Article  CAS  Google Scholar 

  26. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000;192(11):1637–44.

    Article  CAS  Google Scholar 

  27. Wolner ZJ, Marghoob AA, Pulitzer MP, Postow MA, Marchetti MA. A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol. 2018;178:265.

    Article  Google Scholar 

  28. Gauthier Y, Cario Andre M, Taieb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003;16(4):322–32.

    Article  Google Scholar 

  29. Sandoval-Cruz M, Garcia-Carrasco M, Sanchez-Porras R, Mendoza-Pinto C, Jimenez-Hernandez M, Munguia-Realpozo P, et al. Immunopathogenesis of vitiligo. Autoimmun Rev. 2011;10(12):762–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 1INSERM U1035, BMGIC, Immuno-dermatology team, University of Bordeaux, Bordeaux, France

    Katia Boniface & Julien Seneschal

  2. Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Diseases, Saint-André Hospital, University of Bordeaux, Bordeaux, France

    Julien Seneschal

Authors
  1. Katia Boniface
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julien Seneschal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julien Seneschal .

Editor information

Editors and Affiliations

  1. Cutaneous Physiopathology & CIRM, San Gallicano Dermatological Institute, Rome, Italy

    Mauro Picardo

  2. Hôpital Saint André, Service de Dermatologie Adulte et Pédiatrique, INSERM U 1035, Université de Bordeaux, Bordeaux, France

    Alain Taïeb

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Boniface, K., Seneschal, J. (2019). Vitiligo-Like Lesions in Patients with Metastatic Melanoma Receiving Immunotherapies. In: Picardo, M., Taïeb, A. (eds) Vitiligo. Springer, Cham. https://doi.org/10.1007/978-3-319-62960-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-62960-5_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-62958-2

  • Online ISBN: 978-3-319-62960-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation